Form 4: Gilead CFO Dickinson's Equity Transactions

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of restricted stock units, a new grant of RSUs and stock options, and a related tax withholding sale.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., reported multiple equity transactions on March 10, 2026.
• 6,469 Restricted Stock Units (RSUs) vested and converted into common stock.
• 3,147 shares of common stock were disposed of at $148.56 per share to cover tax obligations related to the RSU vesting.
• A new grant of 9,590 Restricted Stock Units (RSUs) was received.
• A new grant of 35,880 non-qualified stock options was received with an exercise price of $148.56 and an expiration date of March 10, 2036.
• Both the new RSU and stock option grants have a four-year vesting schedule: 25% on the first anniversary and 6.25% quarterly thereafter.
• Following these transactions, Dickinson beneficially owns 182,191 shares of common stock, 30,647 Restricted Stock Units, and 35,880 non-qualified stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CFO received significant new equity grants (RSUs and stock options), indicating continued commitment and incentivization, despite a routine tax-related sale of common stock.

Positives

• Acquisition of 6,469 shares of common stock through RSU vesting.
• Grant of 9,590 new Restricted Stock Units, increasing future equity potential.
• Grant of 35,880 new non-qualified stock options, aligning management incentives with shareholder value.

Negatives

• Disposal of 3,147 shares of common stock at $148.56 to cover tax liabilities, resulting in a net decrease in direct common stock ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive equity grants and vesting events are standard practices in the biotechnology and pharmaceutical industries, serving to align executive incentives with long-term company performance and shareholder interests. The specific grants reflect ongoing compensation strategies at Gilead Sciences.

Comparison to Industry Standards

• Executive compensation structures, including grants of Restricted Stock Units and stock options with multi-year vesting schedules, are common across major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson.
• These mechanisms are designed to retain key talent and incentivize performance over several years, aligning with typical industry benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: The new equity grants align the CFO's interests with long-term shareholder value creation. The tax-related sale is a routine event and does not indicate a lack of confidence.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The newly granted Restricted Stock Units will vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter.
• The newly granted non-qualified stock options will vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter.

Key Dates

Recommendation

The filing details routine executive compensation activities, including vesting, tax-related sales, and new equity grants. These transactions are expected and do not provide new fundamental information to warrant a change in investment thesis for Gilead Sciences. The new grants align management incentives, which is a positive, but the overall impact on the stock's valuation is neutral.

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, CFO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation